Evidence map›Paper›PMID 32600728›Full record

ArticleMaterials science & engineering. C, Materials for biological applications2020

Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).

Vineela Parvathaneni, Nishant S Kulkarni, Gautam Chauhan, Snehal K Shukla, Rasha Elbatanony, BrijeshKumar Patel, Nitesh K Kunda, Aaron Muth, Vivek Gupta

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials science & engineering. C, Materials for biological applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Vineela ParvathaneniDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Nishant S KulkarniDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Gautam ChauhanDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Snehal K ShuklaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Rasha ElbatanonyDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA; Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University of Egypt, New Cairo 11835, Egypt.
BrijeshKumar PatelAdvanced Bioderma Corporation, Boca Raton, FL 33487, USA.
Nitesh K KundaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Aaron MuthDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA.
Vivek GuptaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University, Queens, NY 11439, USA. Electronic address: guptav@stjohns.edu.
St. John's University · US

Funding

American Heart Association-American Stroke Association 18AIREA33960072
6 · The paper itself

Abstract

New drug and dosage form development faces significant challenges, especially in oncology, due to longer development cycle and associated scale-up complexities. Repurposing of existing drugs with potential anti-cancer activity into new therapeutic regimens provides a feasible alternative. In this project, amodiaquine (AQ), an anti-malarial drug, has been explored for its anti-cancer efficacy through formulating inhalable nanoparticulate systems using high-pressure homogenization (HPH) with scale-up feasibility and high reproducibility. A 3

Indexed as

A549 CellsAdministration, InhalationAmodiaquineCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCell SurvivalDrug CompoundingDrug RepositioningDrug StabilityHumansHuman Umbilical Vein Endothelial CellsLung NeoplasmsNanoparticlesParticle SizeSpheroids, CellularAmodiaquine3D spheroidAmodiaquineAutophagyDesign of experimentsDrug repurposingHigh pressure homogenizationNon-small cell lung cancerScale-up

Identifiers

PMID32600728
PMCPMC11938939
OpenAlexW3031317685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.